Reuters -- French biotech firm NicOx (NCOX.PA) will buy back the rights to develop and market a drug that seeks to treat eye disease glaucoma from U.S. drugmaker Pfizer (PFE.N) and said it was open to finding another partner.
Reuters -- French biotech firm NicOx (NCOX.PA) will buy back the rights to develop and market a drug that seeks to treat eye disease glaucoma from U.S. drugmaker Pfizer (PFE.N) and said it was open to finding another partner.
